Efficacy, Safety, and Quality of Treatment Satisfaction of Premixed Human and Analogue Insulin Regimens in a Large Cohort of Type 2 Diabetic Patients: PROGENS BENEFIT Observational Study
Table 1
Demographical and clinical characteristics of the studied groups.
Groups
Total
Group I
Group II
Male/female (%)
46.42/53.58
45.05/54.95
51.91/48.09
<0.002
Age (years) (±SD)
65.28 ± 9.29
65.47 ± 9.1
64.65 ± 8.9
NS
BMI (kg/m2) (±SD)
31.17 ± 4.16
31.31 ± 3.85
30.72 ± 4.01
NS
Baseline HbA1c (%; mmol/mol) (±SD)
8.24 ± 1.33
8.31 ± 1.28
7.98 ± 1.31
<0.001
66.6 ± 10.7
67.3 ± 10.3
63.7 ± 10.6
Diabetes duration (years) (±SD)
11.61 ± 6.28
11.58 ± 6.54
11.69 ± 6.72
NS
Insulin therapy duration (years) (±SD)
6.02 ± 4.55
5.97 ± 4.21
6.16 ± 4.31
NS
NS: statically insignificant; n: number of patients; SD: standard deviation; BMI: body mass index; HbA1c: glycated hemoglobin.
